NO328584B1 - Derivater av isosorbidmononitrat, farmasoytiske preparater som omfatter disse og deres anvendelse for fremstilling av medikamenter - Google Patents
Derivater av isosorbidmononitrat, farmasoytiske preparater som omfatter disse og deres anvendelse for fremstilling av medikamenter Download PDFInfo
- Publication number
- NO328584B1 NO328584B1 NO20011778A NO20011778A NO328584B1 NO 328584 B1 NO328584 B1 NO 328584B1 NO 20011778 A NO20011778 A NO 20011778A NO 20011778 A NO20011778 A NO 20011778A NO 328584 B1 NO328584 B1 NO 328584B1
- Authority
- NO
- Norway
- Prior art keywords
- isosorbide
- mononitrate
- group
- compounds
- connection according
- Prior art date
Links
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical class [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 title claims description 18
- 239000003814 drug Substances 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 35
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical group O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 claims description 23
- 229960002479 isosorbide Drugs 0.000 claims description 23
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 16
- 235000001968 nicotinic acid Nutrition 0.000 claims description 16
- 239000011664 nicotinic acid Substances 0.000 claims description 16
- 230000000304 vasodilatating effect Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 229910004679 ONO2 Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000004434 sulfur atom Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000010992 reflux Methods 0.000 description 13
- 239000011521 glass Substances 0.000 description 12
- 239000012298 atmosphere Substances 0.000 description 11
- 238000003760 magnetic stirring Methods 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 229960003827 isosorbide mononitrate Drugs 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 150000002894 organic compounds Chemical class 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 238000004566 IR spectroscopy Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- KHLBHKYZTXYEHP-UHFFFAOYSA-N 2-methylpyridine-3-carbothioyl chloride Chemical compound CC1=NC=CC=C1C(Cl)=S KHLBHKYZTXYEHP-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- JYWNYMJKURVPFH-UHFFFAOYSA-N N-gamma-Acetyl-N-2-Formyl-5-Methoxykynurenamine Chemical compound COC1=CC=C(NC=O)C(C(=O)CCNC(C)=O)=C1 JYWNYMJKURVPFH-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006906 Vascular Ring Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JYWKEVKEKOTYEX-UHFFFAOYSA-N 2,6-dibromo-4-chloroiminocyclohexa-2,5-dien-1-one Chemical compound ClN=C1C=C(Br)C(=O)C(Br)=C1 JYWKEVKEKOTYEX-UHFFFAOYSA-N 0.000 description 1
- GOTPCIOLZMWNHT-UHFFFAOYSA-N 2-ethylpyridine-3-carbothioic s-acid Chemical compound CCC1=NC=CC=C1C(O)=S GOTPCIOLZMWNHT-UHFFFAOYSA-N 0.000 description 1
- GNYWBJRDQHPSJL-UHFFFAOYSA-N 6-acetyl-6-hydroxycyclohexa-2,4-diene-1-carboxylic acid Chemical compound CC(=O)C1(O)C=CC=CC1C(O)=O GNYWBJRDQHPSJL-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 241000021559 Dicerandra Species 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010043087 Tachyphylaxis Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MAHNFPMIPQKPPI-UHFFFAOYSA-N disulfur Chemical class S=S MAHNFPMIPQKPPI-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- -1 pomades Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES009802076A ES2142773B1 (es) | 1998-10-07 | 1998-10-07 | Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida. |
| PCT/ES1999/000316 WO2000020420A1 (es) | 1998-10-07 | 1999-10-04 | Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia disminuida |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20011778D0 NO20011778D0 (no) | 2001-04-06 |
| NO20011778L NO20011778L (no) | 2001-04-06 |
| NO328584B1 true NO328584B1 (no) | 2010-03-22 |
Family
ID=8305360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011778A NO328584B1 (no) | 1998-10-07 | 2001-04-06 | Derivater av isosorbidmononitrat, farmasoytiske preparater som omfatter disse og deres anvendelse for fremstilling av medikamenter |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US20010051735A1 (cs) |
| EP (1) | EP1120419B1 (cs) |
| JP (1) | JP4659214B2 (cs) |
| KR (1) | KR100641801B1 (cs) |
| CN (1) | CN1096465C (cs) |
| AP (1) | AP1555A (cs) |
| AR (1) | AR020538A1 (cs) |
| AT (1) | ATE323707T1 (cs) |
| AU (1) | AU762724B2 (cs) |
| BG (1) | BG65135B1 (cs) |
| BR (1) | BR9914355B1 (cs) |
| CA (1) | CA2346010C (cs) |
| CO (1) | CO5180544A1 (cs) |
| CU (1) | CU23162A3 (cs) |
| CZ (1) | CZ294551B6 (cs) |
| DE (2) | DE19983612T1 (cs) |
| DK (1) | DK1120419T3 (cs) |
| EA (1) | EA003360B1 (cs) |
| EE (1) | EE04374B1 (cs) |
| ES (2) | ES2142773B1 (cs) |
| GB (1) | GB2359810B (cs) |
| GE (1) | GEP20043162B (cs) |
| GT (1) | GT199900173A (cs) |
| HR (1) | HRP20010256B1 (cs) |
| HU (1) | HUP0103937A3 (cs) |
| ID (1) | ID29946A (cs) |
| IL (2) | IL142391A0 (cs) |
| IS (1) | IS2312B (cs) |
| NO (1) | NO328584B1 (cs) |
| NZ (1) | NZ510855A (cs) |
| OA (1) | OA11661A (cs) |
| PA (1) | PA8483901A1 (cs) |
| PE (1) | PE20001083A1 (cs) |
| PL (1) | PL200028B1 (cs) |
| PT (1) | PT1120419E (cs) |
| RS (1) | RS50112B (cs) |
| TR (1) | TR200100961T2 (cs) |
| WO (1) | WO2000020420A1 (cs) |
| YU (1) | YU25201A (cs) |
| ZA (1) | ZA200102836B (cs) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2258365B1 (es) | 2003-10-03 | 2007-12-01 | Lacer, S.A. | Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos. |
| EP1941876A1 (en) * | 2006-12-28 | 2008-07-09 | Lacer, S.A. | Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension |
| ES2332565B1 (es) * | 2007-01-23 | 2010-10-21 | Lacer, S.A. | Uso de derivados de mononitrato de dianhidrohexita como agentes antiinflamatorios. |
| IE20070934A1 (en) | 2007-12-21 | 2009-06-24 | Trinity College Dublin | Efficient aspirin prodrugs |
| EP2719700A1 (en) | 2008-01-09 | 2014-04-16 | Amura Therapeutics Limited | Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| JP5441928B2 (ja) * | 2008-02-07 | 2014-03-12 | ニコックス エス エイ | 一酸化窒素供与化合物 |
| EP2149576A1 (en) | 2008-07-22 | 2010-02-03 | Lacer, S.A. | Isosorbide Nitrates having vasodilating activity |
| EP2149577B1 (en) * | 2008-07-22 | 2011-04-27 | Lacer, S.A. | New stereospecific method for the preparation of dioxa-bicyclooctane compounds |
| EP2177216A1 (en) | 2008-10-13 | 2010-04-21 | Lacer, S.A. | Use of dianhydrohexite mononitrate derivatives as healing agents |
| WO2010055138A1 (en) * | 2008-11-14 | 2010-05-20 | Lacer, S.A. | New stereospecific method for the preparation of dioxa-bicyclooctane compounds |
| EP2199294A1 (en) | 2008-12-19 | 2010-06-23 | Lacer, S.A. | New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds |
| ES2423939T3 (es) * | 2009-09-10 | 2013-09-25 | Cognis Ip Management Gmbh | Derivados de isosorburo gliceril éter y su empleo en aplicaciones de uso doméstico |
| DK2515899T3 (en) | 2009-12-23 | 2016-08-15 | Arca Biopharma Inc | METHODS AND COMPOSITIONS FOR CARDIOVASCULAR DISEASES AND CONDITIONS |
| CN102241687A (zh) * | 2011-05-23 | 2011-11-16 | 中国人民解放军第四军医大学 | 抗缺血/再灌注损伤的药物 |
| CA2839390C (en) | 2011-10-24 | 2015-09-15 | Nicox S.A. | Quinone based nitric oxide donating compounds |
| CA2902009A1 (en) * | 2013-03-05 | 2014-09-12 | Archer Daniels Midland Company | Isohexide monotriflates and process for synthesis thereof |
| WO2014169976A1 (en) | 2013-04-18 | 2014-10-23 | Nicox Science Ireland | Quinone based nitric oxide donating compounds |
| CN104650108B (zh) * | 2013-11-18 | 2017-05-24 | 富力 | 连翘脂素硫酸酯及其衍生物、制备方法及其应用 |
| CN105461731B (zh) * | 2014-08-07 | 2017-05-24 | 富力 | 连翘脂素布洛芬酯、其制备及其应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1356374A (fr) | 1963-02-12 | 1964-03-27 | Machine à fonctions multiples pour le travail du bois | |
| GB1356374A (en) | 1971-04-29 | 1974-06-12 | American Home Prod | Mononitrate esters of 1,3 3,6-dianhydro-d-glucitol |
| US3886196A (en) | 1973-02-07 | 1975-05-27 | Phillips Petroleum Co | Magnesium-aluminum-silicate-phosphate catalysts for ammonialytic cleavage of lactams to form omega-aminonitriles |
| DE3028289C2 (de) | 1980-07-25 | 1986-11-27 | Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe | 2-O- und 5-O-substituierte 1.4;3.6-Dianhydro-hexit-mononitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen |
| DE3248548A1 (de) | 1982-12-29 | 1984-07-05 | Heinrich Mack Nachf., 7918 Illertissen | Acylderivate von 1,4:3,6-dianhydro-hexiten, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE3421072A1 (de) | 1984-06-06 | 1985-12-12 | Heinrich Mack Nachf., 7918 Illertissen | 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| DE3602067A1 (de) | 1986-01-24 | 1987-07-30 | Mack Chem Pharm | 2,6-dioxabicyclo(3.3.0)octan-derivate, ihre herstellung und verwendung als arzneimittel |
| DE3606634A1 (de) | 1986-02-28 | 1987-09-03 | Mack Chem Pharm | Isohexid-nucleoside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| IT1204571B (it) * | 1987-05-08 | 1989-03-10 | Chiesi Farma Spa | Esteri di 1,4:3,6-dianidrosorbitolo-2-mononitrato e 5-mononitrato,loro procedimento di preparazione e loro composizioni farmaceutiche |
| DE3741005A1 (de) | 1987-12-03 | 1989-06-15 | Mack Chem Pharm | Aminopropanol-derivate von 1,4:3,6-dianhydro-hexit-nitraten, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JP2628756B2 (ja) * | 1988-09-15 | 1997-07-09 | シュバルツファルマ アクチェンゲゼルシャフト | 新規有機ニトレート及びそれらの製造方法 |
| US5428061A (en) | 1988-09-15 | 1995-06-27 | Schwarz Pharma Ag | Organic nitrates and method for their preparation |
| US4891373A (en) * | 1988-11-23 | 1990-01-02 | Pfizer Inc. | Aminopropanol derivatives of 1,4:3,6-dianhydrohexitol nitrates, processes for their preparation and their use as medicaments |
| CA2014520C (en) | 1989-04-17 | 1996-07-16 | Fumio Suzuki | Hexitol derivatives |
| NL9001955A (nl) * | 1990-09-05 | 1992-04-01 | Cedona Pharm Bv | Nieuwe thiazolidinederivaten. |
| FR2680173A1 (fr) * | 1991-08-07 | 1993-02-12 | Hoechst Lab | Nitrates organiques, leurs procedes de preparation et leur utilisation dans le traitement de maladies cardiovasculaires . |
| ATE172183T1 (de) * | 1992-07-30 | 1998-10-15 | Cal Int Ltd | Ester und kombinationen von einem organischen nitrat und einem salicyclat |
| IL120531A (en) | 1997-03-26 | 2006-12-31 | Yissum Res Dev Co | Nitric oxide donors and pharmaceutical compositions containing them |
-
1998
- 1998-10-07 ES ES009802076A patent/ES2142773B1/es not_active Expired - Fee Related
-
1999
- 1999-09-30 AR ARP990104928A patent/AR020538A1/es active IP Right Grant
- 1999-10-04 PE PE1999001005A patent/PE20001083A1/es not_active Application Discontinuation
- 1999-10-04 EP EP99949015A patent/EP1120419B1/en not_active Expired - Lifetime
- 1999-10-04 NZ NZ510855A patent/NZ510855A/xx not_active IP Right Cessation
- 1999-10-04 CZ CZ20011257A patent/CZ294551B6/cs not_active IP Right Cessation
- 1999-10-04 HR HR20010256A patent/HRP20010256B1/xx not_active IP Right Cessation
- 1999-10-04 OA OA1200100085A patent/OA11661A/en unknown
- 1999-10-04 BR BRPI9914355-0A patent/BR9914355B1/pt not_active IP Right Cessation
- 1999-10-04 WO PCT/ES1999/000316 patent/WO2000020420A1/es not_active Application Discontinuation
- 1999-10-04 JP JP2000574532A patent/JP4659214B2/ja not_active Expired - Fee Related
- 1999-10-04 AT AT99949015T patent/ATE323707T1/de not_active IP Right Cessation
- 1999-10-04 EE EEP200100207A patent/EE04374B1/xx not_active IP Right Cessation
- 1999-10-04 AP APAP/P/2001/002128A patent/AP1555A/en active
- 1999-10-04 HU HU0103937A patent/HUP0103937A3/hu unknown
- 1999-10-04 YU YU25201A patent/YU25201A/sh unknown
- 1999-10-04 ES ES99949015T patent/ES2257871T3/es not_active Expired - Lifetime
- 1999-10-04 DE DE19983612T patent/DE19983612T1/de not_active Ceased
- 1999-10-04 IL IL14239199A patent/IL142391A0/xx active IP Right Grant
- 1999-10-04 RS YUP-252/01A patent/RS50112B/sr unknown
- 1999-10-04 EA EA200100422A patent/EA003360B1/ru not_active IP Right Cessation
- 1999-10-04 ID IDW00200101008A patent/ID29946A/id unknown
- 1999-10-04 KR KR1020017004374A patent/KR100641801B1/ko not_active Expired - Fee Related
- 1999-10-04 PL PL347030A patent/PL200028B1/pl not_active IP Right Cessation
- 1999-10-04 DK DK99949015T patent/DK1120419T3/da active
- 1999-10-04 AU AU62041/99A patent/AU762724B2/en not_active Ceased
- 1999-10-04 DE DE69930949T patent/DE69930949T2/de not_active Expired - Lifetime
- 1999-10-04 GB GB0111172A patent/GB2359810B/en not_active Expired - Fee Related
- 1999-10-04 TR TR2001/00961T patent/TR200100961T2/xx unknown
- 1999-10-04 CN CN99811802A patent/CN1096465C/zh not_active Expired - Fee Related
- 1999-10-04 CA CA002346010A patent/CA2346010C/en not_active Expired - Fee Related
- 1999-10-04 PT PT99949015T patent/PT1120419E/pt unknown
- 1999-10-04 GE GEAP19995886A patent/GEP20043162B/en unknown
- 1999-10-06 CO CO99063420A patent/CO5180544A1/es not_active Application Discontinuation
- 1999-10-07 GT GT199900173A patent/GT199900173A/es unknown
- 1999-10-07 PA PA19998483901A patent/PA8483901A1/es unknown
-
2001
- 2001-03-29 IS IS5910A patent/IS2312B/is unknown
- 2001-04-03 IL IL142391A patent/IL142391A/en not_active IP Right Cessation
- 2001-04-04 CU CU83A patent/CU23162A3/es not_active IP Right Cessation
- 2001-04-05 ZA ZA200102836A patent/ZA200102836B/xx unknown
- 2001-04-06 US US09/827,868 patent/US20010051735A1/en not_active Abandoned
- 2001-04-06 BG BG105417A patent/BG65135B1/bg unknown
- 2001-04-06 NO NO20011778A patent/NO328584B1/no not_active IP Right Cessation
-
2003
- 2003-04-28 US US10/424,828 patent/US6858632B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO328584B1 (no) | Derivater av isosorbidmononitrat, farmasoytiske preparater som omfatter disse og deres anvendelse for fremstilling av medikamenter | |
| CZ294549B6 (cs) | Montážní spojka pro úseky vedení kabelů a výsledné úseky vedení kabelů | |
| CA2540500C (en) | Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof | |
| WO2014138212A1 (en) | CaMKII INHIBITORS AND USES THEREOF | |
| CN116655557B (zh) | 苯并噻唑类化合物、其制备方法及应用 | |
| CN108727293B (zh) | 1，2，8-氧代二氮杂环壬-9-酮衍生物及其合成方法 | |
| JP2021525784A (ja) | チエノ［２，３−ｃ］ピリダジン−４（１Ｈ）−オン系誘導体及びその使用 | |
| JP7575764B2 (ja) | ジピロメテン－１－オン系化合物及びその製造方法 | |
| JPH05186458A (ja) | 新規なベンゾピラン誘導体 | |
| EP0842924B1 (en) | Pyridine intermediates, useful in the synthesis of beta-adrenergic receptor agonists | |
| SK43499A3 (en) | New pentaerythritol derivatives, their production and use and intermediates for their synthesis | |
| CA3210658A1 (en) | Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis | |
| HK1039125A (en) | Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance | |
| US3912767A (en) | Novel sulfonate esters of 2-hydroxy-3-(methylthio)-1,4-naphthoquinone | |
| MXPA01003568A (en) | Derivatives of isosorbid mononitrate, utilization as vasodilator agents with reduced tolerance | |
| WO1995023796A1 (fr) | Derive de guanylhydrazone | |
| JPH08113574A (ja) | ピリダジノインドール誘導体 | |
| JPS62153263A (ja) | 三環性又は四環性化合物 | |
| JPH04270291A (ja) | チアジノ〔６，５−ｂ〕インドリジン誘導体 | |
| JPH02247161A (ja) | ペンタジエン酸誘導体及びその製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |